A novel tumor suppressor, PTEN/MMAC1, was recently found on chromosome 10q23 and mutations of this gene were described in about 20% of primary glioblastomas (GBM) and 60% of GBM cell lines. To de®ne further the relevance of PTEN/MMAC1 mutations in GBM we investigated by SSCP analysis its coding sequence in 44 gliomas, including 41 GBM, and in 21 short-term cultures (15 GBM and six malignant astrocytomas). Loss of heterozygosity (LOH) at 10q23 was present in at least one marker in the vicinity of the PTEN/MMAC1 locus in 59% of the informative GBM (primary tumors and cell cultures). SSCP variant bands were found in seven primary GBM (17%) and in one short-term GBM culture and sequence analysis con®rmed the presence of somatic mutations in all these cases (®ve missense, one splicing mutation and two small deletions). These data indicate that PTEN/MMAC1 is inactivated in a subset of GBM and suggest that the high mutation frequency previously found in GBM established cell lines re¯ects culture condition artifacts rather than the true mutation frequency in vivo. Other suppressors, located on chromosome 10q, may also have a critical role in glioma tumorigenesis.
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Keywords: glioblastoma; chromosome 10; tumor suppressor; mutation In recent years the de®nition of the molecular steps underlying the neoplastic progression from low-grade gliomas to glioblastoma multiforme (GBM), the most frequent and aggressive of primary brain tumors, has made considerable progress. A reasonable consensus has been obtained in considering mutations of the p53 tumor suppressor as one of the initial genetic changes (reviewed by Bogler et al., 1995) . Lack of genetic material at the short arm of chromosome 9, associated with mutations of the p16 gene, and at the long arm of chromosome 19, together with ampli®cation of the EGF receptor are likely to be later events, usually accompanying the passage from a dierentiated to an anaplastic, malignant astrocytoma (AA) (reviewed by von Deimling et al., 1995; and by Louis and Gusella, 1995) . We and others have found that the formation of GBM, either de novo or from a pre-existing AA, almost inevitably require the lack of genetic material on chromosome 10 (Magnani et al., 1994 and references therein) . In a large percentage of GBM one entire copy of chromosome 10 is lost, but partial deletions are also frequent, especially on the long arm of this chromosome. Obviously, the frequency of these genetic events points to the presence of one or more tumor suppressor genes whose inactivation is critical for GBM formation.
The search for such gene(s) has recently led to the identi®cation of PTEN/MMAC1 (Phosphatase and Tensin homolog deleted on chromosome TEN/Mutated in Multiple Advanced Cancers 1) Steck et al., 1997) . The PTEN/MMAC1 gene product contains a tyrosine phosphatase domain and has a phosphatase activity (Li and Sun, 1997; Myers et al., 1997) which may be relevant for its anti-neoplastic function, since a number of oncoproteins acts by phosphorylating tyrosine residues (Hunter, 1997) . It also shows homologies to tensin, a cytoskeletal protein that binds actin and is localized at focal adhesions (Lo et al., 1994) , and to auxillin, a cytoplasmic protein with a role in uncoating clathrin-coated vesicles (Ungewickell et al., 1995) . Thus, the tumor suppressor role of PTEN/MMAC1 could also imply the control of delicate interactions between the cytoskeleton and the extracellular matrix, interactions that are likely to be perturbed to allow in®ltration and migration of neoplastic cells.
Somatic mutations of PTEN/MMAC1 have been found in prostate, breast and brain cancers Steck et al., 1997) , while germinal mutations have been described in Cowden disease, a rare dominant condition characterized by the presence of multiple hamartomas and by increased frequency of breast, thyroid and brain tumors . The PTEN/MMAC1 gene maps to chromosome 10q23 Steck et al., 1997) . Even though this region is deleted in a large fraction of GBM, a higher frequency of deletions has been found in regions that are telomeric to 10q23 (Rasheed et al., 1995; Albarosa et al., 1996) , implying that more than one suppressor is present on 10q. This suggestion is also supported by the relatively low frequency of PTEN/MMAC1 mutations that have been found in primary GBM Steck et al., 1997) . In established cell lines, however, a large number of mutations was detected (ibidem). To assess further the contribution of PTEN/ MMAC1 mutations in GBM we have investigated by SSCP and sequence analysis 44 primary gliomas (40 adult GBM, one pediatric GMB, one anaplastic astrocytoma, one gemistocytic and one protoplasmic astrocytoma) and 21 short-term cultures of malignant gliomas (15 GBM, three anaplastic astrocytomas and three anaplastic oligoastrocytomas).
The nine exons of PTEN/MMAC1 were PCRampli®ed and analysed by SSCP as described in Table  1 . Variant bands, not present when the corresponding lymphocyte DNA was analysed, were identi®ed and sequenced in seven of the 44 DNA examined. Results are summarized in Table 2 . In one GBM the acceptor site of intron 2 was mutated, causing a AG to CG change. The modi®cation of this nucleotide, which is invariably present in the 3' region of spliced introns, very likely should cause an abnormal processing of PTEN/MMAC1 mRNA. In this case, as in the other cases of mutations that we report, the sequence of the corresponding PTEN/MMAC1 fragments from lymphocyte DNA was normal (DNA sequencing was performed on an automatic sequencer from Applied Biosystems, model 373A, using the protocols suggested by the manufacturer). Missense mutations were found in four GBM. Two point mutations were detected at exon 3, a GAT to TAT change at codon 58 and a TAC to CAC change at codon 68 implying, respectively, a tyrosine for aspartate and a histidine for tyrosine substitution. Two other point mutations were found at exon 6, GGA to AGA at codon 165 and AGT to ATT at codon 170 (Figure 1a) , predicting, respectively an arginine for glycine and an isoleucine for serine substitution. The four missense mutations found in primary GBM aect amino acid residues that are conserved in auxilin, and, in one case, also in tensin (see the sequence alignment in ®gure 3C of . This is also true for the L57W mutation described by Steck et al. (1997) . However a larger number of observations and detailed information on structure-function relationships of auxilin and tensin are required to assess the functional relevance of these mutations.
Finally, two four-nucleotide deletions, aecting nt 951 ± 954 and nt 956 ± 959, respectively, were present at exon 8 in two other GBM. These deletions would cause a premature stop of PTEN/MMAC1 translation at codon 319 and 342, respectively. Interestingly, deletions of nucleotides 956 ± 959 and 955 ± 957, have been reported in two GBM by Steck et al. (1997) .
The relevance of these mutations for GBM formation is not only suggested by their absence in constitutive DNA of these patients but also by their occurrence in tumors with evidence for loss of heterozygosity in the chromosomal region containing PTEN/MMAC1. This evidence was obtained by microsatellite analysis with markers D10S579 and D10S541,¯anking the PTEN/MMAC1 locus, respectively, on the centromeric and telomeric side. The ampli®cation of these microsatellites was performed by PCR on genomic DNA, using the following primers: D10S579-F GCGTTGTCTCCTTCTAACAC; D10S579-R CACCCAGCCAATGCTGCTC; D10S541-F CACA-GACATCTCACAACC; D10S541-R GTGAATAGTT-CAGGGATGG.
The results of this analysis are shown in Table 3 and indicate that LOH was present in at least one locus in 25/39 primary informative GBM (64%). All patients with PTEN/MMAC1 mutations scored positive at LOH analysis (six showed LOH at one marker and were not informative at the other; one showed LOH at both markers).
The frequency of PTEN/MMAC1 mutations was also investigated in 21 short-term cultures derived from malignant gliomas (15 GMB, three anaplastic astrocytomes and three anaplastic oligo-astrocytomas). These cultures were obtained by mechanical disruption of the surgical sample, seeding in culture¯asks containing RPMI supplemented with 10% FCS and subsequent removal of non-adherent cells. For each culture no more than four passages were performed before DNA or RNA extraction. SSCP and sequence analysis of DNA from these cells revealed only one point mutation at codon 129 in GBM culture T63, causing a GGA to AGA base change and a glycine to arginine substitution in the tyrosine phosphatase signature motif (Figure 1b ). An identical mutation Genomic DNA was obtained from surgical specimens of GBM, from lymphocytes of the corresponding patients and from cell lines using a nucleic acid extraction kit based on cell lysis with guanidine thyocianate (IsoQuick, MicroProbe). Nine fragments, each containing the PTEN/MMAC1 exon indicated in the ®rst column, were ampli®ed in 20 ml of reaction mixture, using 150 ng of genomic DNA and primers of the FA/RP series (FB/RR for exon 8) described by Steck et al. (1997) . Annealing temperatures are reported in the second column. PCR cycles were usually 35 (30 s at 958C, 30 s at the hybridization temperature reported in Table 1 and 45 s at 728C).
Half of the PCR reaction was digested with the restriction enzymes indicated in column 3 in order to obtain fragments of 100 ± 250 bp. Digestion products were precipitated and analysed by SSCP as described by Tenan et al. (1995) , using a 8% polyacrylamide gel (39:1) and 16TBE (when analysing exon 9, 10% glycerol was added to the gel). Gels were run at 48C, overnight at 460 V. In case of exons 5 and 7 the digestion with enzymes reported above caused the formation of small fragments unsuitable for SSCP analysis. To include into SSCP analysis also these small fragments, a second PCR on genomic DNA was performed with the following primers: Exon 5 F2: ACCACAGTTGCACAATATCC, R2 CACATATC-ATTACACCAGTTCG (Annealing T:548C); Exon 7 F2 ACACG ACGGGAAGACAAGTT, R2 GATATTTCTCCCAATGAAAGTA (Annealing T:558C) 782 from AG A/G Silent was also described in a primary GBM by and in one GBM and one follicular adenoma of patients with Cowden disease . LOH analysis was also performed on cell cultures considering markers D10S579 and D10S541, two intragenic polymorphisms (A/G at intron 1 and ATCTT at intron 4, see Table 1 ) and the karyotype. These investigations suggested that 7/15 GBM cultures (47%) were hemyzygous (including the one with the mutation) and 8/15 heterozygous in the PTEN/MMAC1 region. In the six anaplastic gliomas hemyzygosity of this region of 10q was only present in one tumor and absent in the other ®ve. The lower frequency of LOH in cell cultures than in primary GBM (47% vs 64%) might imply that in few cases cells that are not representative of the originary tumor are growing in culture. An extensive characterization of these shortterm cultures, comparing microsatellite analysis in culture cells and in the corresponding primary tumor and considering immunocytochemical markers such as GFAP, should help to address this issue. Even with this caveat, however, our investigation of PTEN/ MMAC1 mutations in cultures derived from malignant gliomas, clearly indicates that such mutations are not very frequent. This apparent low frequency of PTEN/MMAC1 mutations led us to the investigation of alternative mechanisms of inactivation of this gene. In particular, the full-length cDNA of PTEN/MMAC1 contains a long 5' untranslated region with multiple islands of CGG repeats which could be the target of methylationinduced transcriptional silencing, as in the case of the p16 gene (Merlo et al., 1995) . We investigated by RT ± PCR in 15 cultures of malignant gliomas (11 GBM, 3 AOA and 1 AA) the expression of PTEN/MMAC1 with two sets of primers amplifying, respectively, the full-length cDNA and a portion of coding sequence of 647 bp spanning exons 5 ± 8 (nt 302 through 949, starting from the initial ATG). The results of these RT ± PCR experiments demonstrated that PTEN/ MMAC1 was transcribed in all the examined cell cultures and therefore indicate that transcriptional silencing is not a relevant mechanism of PTEN/ MMAC1 inactivation in GBM.
Control ampli®cation for these experiments were performed with primers for the HGPRT gene, located on two dierent exons separated by a small intron of about 180 bp. These control ampli®cations veri®ed the quality and the amount of the available cDNA and demonstrated that genomic DNA contamination was negligible. This is particularly relevant since with the set of internal primers for PTEN/MMAC1 a PCR product with a size corresponding to spliced exons 5 ± 8 could be ampli®ed from genomic DNA. The partial DNA sequence of this product demonstrated several single base changes, suggesting its derivation from a PTEN/MMAC1 pseudogene. Interestingly, these same base changes were also described in a recent report on PTEN/MMAC1 mutations in breast cancers by Rhei et al. (1997) . These sequence changes were de®ned as polymorphisms, but they likely derive from the PTEN/ MMAC1 pseudogene that was ampli®ed by PCR primers derived from the cDNA sequence.
In conclusion, our investigations on the PTEN/ MMAC1 gene lead to two main conclusions: (i) PTEN/ MMAC1 is mutated in a subset of primary GBM. We found 7/41 GBM bearing such mutations, a 17% that rises to 28% (7/25) if we consider GBM with evidence of LOH. This frequency is in agreement with the ®ndings of and Steck et al. (1997) . However, some underestimation of the actual presence of mutations might be due to the fact that about 20% of sequence alterations could be missed by the SSCP technique (Sheeld et al., 1993) . (ii), PTEN/MMAC1 mutations are present with low frequency also in GBM primary cultures, since we only found one point mutation in the 15 cultures considered. This frequency is much lower than the one found in established GBM cell lines by Li et al. (5/8 GBM cell lines were mutated, 63%) and Steck et al. (10/15, 59%) . This may imply that, as in the case of the p16 tumor suppressor (Spruck et al., 1994) , cells harboring PTEN/MMAC1 mutations, either caused de novo in a situation of genetic instability or by clonal selection, become predominant after long-term passaging.
Overall these ®ndings con®rm that PTEN/MMAC1 may have a role in glioma tumorigenesis. Such a role, however, is present in a subset of GBM, in agreement with deletion mapping studies (Rasheed et al., 1995; Albarosa et al., 1996) that point to a very high frequency of genetic losses in a region telomeric to the PTEN/MMAC1 locus. Interestingly, during the revision of this manuscript, a new candidate tumor suppressor on such telomeric region, DMBT1, was described and found deleted in malignant brain tumors (Mollenhauer et al., 1997) .
